Fuente: Labiotech Lugar: In Depth Delve into the field of pulmonary hypertension as GSK places a $950 million bet on a candidate following the footsteps of Winrevair.
The post Pulmonary hypertension after Winrevair: where GSK’s $950M bet fits  appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.